Effectiveness of Fluticasone Furoate–Vilanterol for COPD in Clinical Practice | Zendy

Jørgen Vestbo | Zendy; David Leather | Zendy; Nawar Diar Bakerly | Zendy; John P. New | Zendy; Martin Gibson | Zendy; Sheila McCorkindale | Zendy; Susan Collier | Zendy; Jodie Crawford | Zendy; Lucy Frith | Zendy; Catherine Harvey | Zendy; Henrik Svedsäter | Zendy; Ashley Woodcock | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effectiveness of Fluticasone Furoate–Vilanterol for COPD in Clinical Practice

Author(s) -

Jørgen Vestbo,

David Leather,

Nawar Diar Bakerly,

John P. New,

Martin Gibson,

Sheila McCorkindale,

Susan Collier,

Jodie Crawford,

Lucy Frith,

Catherine Harvey,

Henrik Svedsäter,

Ashley Woodcock

Publication year - 2016

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1608033

Subject(s) - medicine , fluticasone propionate , exacerbation , copd , randomized controlled trial , clinical trial , confidence interval , fluticasone , physical therapy , pediatrics , corticosteroid

Evidence for the management of chronic obstructive pulmonary disease (COPD) comes from closely monitored efficacy trials involving groups of patients who were selected on the basis of restricted entry criteria. There is a need for randomized trials to be conducted in conditions that are closer to usual clinical practice.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research